Cabio Biotech (Wuhan) Co., Ltd. (SHA:688089)

Market Cap	4.33B
Revenue (ttm)	594.54M
Net Income (ttm)	144.90M
Shares Out	168.31M
EPS (ttm)	0.87
PE Ratio	29.51
Forward PE	28.21
Dividend	0.20 (0.79%)
Ex-Dividend Date	Jun 26, 2024

Volume	2,257,444
Average Volume	5,174,316
Open	25.51
Previous Close	25.33
Day's Range	25.30 - 26.25
52-Week Range	12.11 - 30.12
Beta	0.62
RSI	57.51
Earnings Date	Apr 29, 2025

About Cabio Biotech (Wuhan)

Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. Its products are used in infant formula food, health food, dietary supplements, and other fields for special medical purposes, pet nutrition food, economic animal feed, personal care and cosmetics, and other fields. The company was founded in 1999 and is based in Wuhan, the People’s Republic of China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 565
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688089

Financial Performance

In 2024, Cabio Biotech (Wuhan)'s revenue was 555.59 million, an increase of 25.19% compared to the previous year's 443.80 million. Earnings were 124.21 million, an increase of 35.94%.